Saúde Pública

Impactos global, regional e nacional da osteoartrite de quadril de 1990 a 2019: estimativas do 2019 Global Burden of Disease Study.

20 Jan, 2022 | 20:51h

Global, regional, and national burdens of hip osteoarthritis from 1990 to 2019: estimates from the 2019 Global Burden of Disease Study – Arthritis Research & Therapy

Grandes desafios na saúde oftálmica global: processo de priorização global usando o método Delphi.

20 Jan, 2022 | 20:38h

Grand Challenges in global eye health: a global prioritisation process using Delphi method – The Lancet Health Longevity

Podcast relacionado: Author interview

Comentário no Twitter

Roughly 2.2 billion people have vision impairment—yet 50% of sight loss is preventable.

In @LancetLongevity, Jacqueline Ramke & colleagues identify the key issues that must be addressed to improve global #EyeHealth in the context of an ageing population.https://t.co/banTov24VX pic.twitter.com/tLSZaUYXhw

— The Lancet (@TheLancet) January 6, 2022

Impactos global, regional e nacional de 12 distúrbios mentais em 204 países e territórios, 1990–2019: análise sistemática para o Global Burden of Disease Study 2019.

13 Jan, 2022 | 21:08h

Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 – The Lancet Psychiatry

Comentário convidado: The true global disease burden of mental illness: still elusive – The Lancet Psychiatry (necessário cadastro gratuito)

Estimativa de prevalência global de demência em 2019 e prevalência prevista para 2050: uma análise do Global Burden of Disease Study 2019.

12 Jan, 2022 | 12:52h

Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 – The Lancet Public Health

Comunicado de imprensa: Global dementia cases set to triple by 2050 unless countries address risk factors – The Lancet

Comentários:

Forecasting the prevalence of dementia – The Lancet Public Health

Dementia cases expected to almost triple across the world by 2050 – BBC

Number of adults with dementia to exceed 150m by 2050, study finds – The Guardian

Comentário no Twitter (fio – clique para saber mais)

🆕✨First #GBDstudy forecasts global #dementia cases set to triple by 2050 (up from 57m in 2019 to expected 153m people) unless countries address risk factors: #smoking, #obesity, #HighBloodSugar, & low #education🧵👇

Published in @TheLancet @TheLancetPH https://t.co/GccTPRroEV

— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) January 7, 2022

Incidência de mortalidade, anos de vida perdidos e anos vividos com incapacidade para 29 grupos de câncer de 2010 a 2019: análise sistemática para o Global Burden of Disease Study 2019.

12 Jan, 2022 | 12:47h

Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019 – JAMA Oncology

Comunicado de imprensa: Cancer deaths rose to 10 million worldwide in 2019: Recent trends also highlight global disparities in cancer burden – Institute for Health Metrics and Evaluation

Nova diretriz AAP recomenda o rastreamento de rotina para HIV para todos os jovens de 15 anos ou mais.

10 Jan, 2022 | 12:20h

Adolescents and Young Adults: The Pediatrician’s Role in HIV Testing and Pre- and Postexposure HIV Prophylaxis – Pediatrics

Comentário: Pediatricians Can Play Key Role in HIV Testing, Prophylaxis – HealthDay

Estudo randomizado | Tratamento antirretroviral de baixo custo e de fácil adesão, baseado em dolutegravir, como terapia de primeira ou segunda linha foi não inferior ao tratamento padrão da infecção por HIV-1 em crianças.

10 Jan, 2022 | 12:13h

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Easy-to-take medicine better at suppressing HIV in children – University College London

Comentários no Twitter

Dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents starting first- or second-line therapy for HIV type 1 infection. Dolutegravir-based ART was superior to standard-care ART. https://t.co/PP0XaEVswO pic.twitter.com/pQvhjdXcUk

— NEJM (@NEJM) December 29, 2021

Visual Abstract: Dolutegravir as First- or Second-Line HIV Treatment in Children https://t.co/2RIg9uH2V1 pic.twitter.com/mDr1Z6l6CJ

— NEJM (@NEJM) January 4, 2022

FDA aprova o primeiro tratamento injetável para profilaxia pré-exposição ao HIV.

10 Jan, 2022 | 12:09h

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention – U.S. Food & Drug Administration

Comentários:

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention – NIH News Releases

A new injection to prevent HIV, rather than pills, is a game-changer, scientists say – NPR

Conteúdos relacionados:

CDC Guidance: Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents

Study Shows High Burden of STI Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection

USPSTF Statement: Preexposure Prophylaxis for the Prevention of HIV Infection

British Guidelines on the Use of HIV Pre–exposure Prophylaxis (PrEP) (várias diretrizes sobre o tema)

New Protocol for HIV Prevention Drug Reduces The Number Of Pills Required

Segurança no aborto com o uso de mifepristona no Canadá.

16 Dez, 2021 | 12:51h

Abortion Safety and Use with Normally Prescribed Mifepristone in Canada – New England Journal of Medicine

Comunicado de imprensa: Prescribing the abortion pill without restrictions is safe and effective, study finds – University of British Columbia

Opinião | Tomadores de decisão precisam constantemente de síntese de evidência atualizada.

16 Dez, 2021 | 12:41h

Decision makers need constantly updated evidence synthesis – Nature